Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients with type 1 diabetes and its complications

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 3, 2012, Pages 229-237

  Lu, Shangsu ^a,b,c   Purohit, Sharad ^c   Sharma, Ashok ^c   Zhi, Wenbo ^c   He, Mingfang ^b,c   Wang, Yiqian ^d   Li, Chao Jun ^a   She, Jin Xiong ^c  

^a NANJING NORMAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Zhangjiagang Entry Exit Inspection and Quarantine Bureau   (China)

Author keywords

Complications; Diabetes; Insulin resistance; Insulin like growth factor binding proteins (IGFBPS)

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 6;

ADULT; AGE; ARTICLE; BLINDNESS; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

EID: 84864313055     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Firth SM and Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
2. Le Roith D. The insulin-like growth factor system. Exp Diabesity Res 2003; 4: 205-212.
3. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010; 62: 199-236.
4. Hwa V, Oh Y, and Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-787.
5. Korevaar TIM, Ragazzoni F, Weaver A, Karavitaki N and Grossman AB. IGF2-induced hypoglycemia unresponsive to everolimus. QJM: Int J Med 2012; doi:10.1093/qjmed/hcr249.
6. Barra WF, Castro G, Hoff AO, Siqueira SA, and Hoff PM. Symptomatic hypoglycemia related to inappropriately high igf-ii serum levels in a patient with desmoplastic small round cell tumor. Case Report Med 2010; 2010: 684045
7. Sima AA, Li ZG, and Zhang W. The insulin-like growth factor system and neurological complications in diabetes. Exp Diabesity Res 2003; 4: 235-256.
8. Rajaram S, Baylink DJ, and Mohan S. Insulinlike growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-831.
9. Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, and Rechler MM. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem 1993; 268: 9246-9254.
10. Mohamed-Ali V, Pinkney JH, Panahloo A, Cwyfan-Hughes S, Holly JM, and Yudkin JS. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. Clin Endocrinol (Oxf) 1999; 50: 221-228.
11. Feldmann B, Jehle PM, Mohan S, Lang GE, Lang GK, Brueckel J, and Boehm BO. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Horm IGF Res 2000; 10: 53-59.
12. Ruan W and Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 2010; 47: 5-14.
13. Wheatcroft SB and Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and-2: implications for metabolic homeostasis. Trends Endocrinol Metab 2009; 20: 153-162.
14. Bayes-Genis A, Conover CA, and Schwartz RS. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000; 86: 125-130.
15. Livingstone C and Ferns G.A. Insulin-like growth factor-related proteins and diabetic complications. Br J Diabetes Vasc Dis 2003; 3: 326-331.
16. Carmichael SK, Johnson SB, Baughcum A, North K, Hopkins D, Dukes MG, She JX, and Schatz DA. Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genet Med 2003; 5: 77-83.
17. Zhi W, Sharma A, Purohit S, Miller E, Bode B, Anderson SW, Reed JC, Steed RD, Steed L, Hopkins D, and She JX. Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays. Mol Cell Proteomics 2011; 10: M111.012203.
18. Sekhon JS and Grieve RD. A matching method for improving covariate balance in costeffectiveness analyses. Health Econ 2012; 21: 695-714.
19. R Development Core Team. R: A language and environment for statistical computing 2010; 3-900051-07-0.
20. Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van DJ, and Juul A. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulinlike growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 1999; 13: 166-172.
21. Sireesha M, Sambasivan V, Kumar VK, Radha S, Raj AY, and Qurratulain H. Relevance of insulin-like growth factor 2 in the etiopathophysiology of diabetic nephropathy: possible roles of phosphatase and tensin homolog on chromosome 10 and secreted protein acidic and rich in cysteine as regulators of repair. J Diabetes 2009; 1: 118-124.
22. Jehle PM, Schulten K, Schulz W, Jehle DR, Stracke S, Manfras B, Boehm BO, Baylink DJ, and Mohan S. Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to-6 and their relationship to bone metabolism in osteoporosis patients. Eur J Intern Med 2003; 14: 32-38.
23. van DJ, Ringeling AM, Shmueli SS, Kuijpers MC, Hokken-Koelega AC, van Buul-Offers SC, and Jansen M. Circulating levels of human insulinlike growth factor binding protein-6 (IGFBP-6) in health and disease as determined by radioimmunoassay. Clin Endocrinol (Oxf) 1999; 50: 601-609.
24. Rosenfel RG and Roberts CT. The IGF system: molecular biology, physiology, and clinical applications. 1999.
25. Garcia-Fernandez M, Sierra I, Puche JE, Guerra L, and Castilla-Cortazar I. Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats. J Transl Med 2011; 9: 123
26. Castilla-Cortazar I, Garcia-Fernandez M, Delgado G, Puche JE, Sierra I, Barhoum R and Gonzalez-Baron S. Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats. J Transl Med 2011; 9: 103
27. Kratz G, Lake M, and Gidlund M. Insulin like growth factor-1 and-2 and their role in the reepithelialisation of wounds; interactions with insulin like growth factor binding protein type 1. Scand J Plast Reconstr Surg Hand Surg 1994; 28: 107-112.
28. Kratz G, Lake M, Ljungstrom K, Forsberg G, Haegerstrand A and Gidlund M. Effect of recombinant IGF binding protein-1 on primary cultures of human keratinocytes and fibroblasts: selective enhancement of IGF-1 but not IGF-2-induced cell proliferation. Exp Cell Res 1992; 202: 381-385.